|
[Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] |
Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 533. 2017 Authors' conclusions No evidence was found comparing the three trademarks of commercially available dimethyl-fumarate in Argentina: Tecfidera® (Biogen), Catira® (Bagó) and Dimeful® (Gador).
Based on the Argentina National Agency for Drugs, Food and Medical Technology (ANMAT), the three trademarks contain the same drug, at the same dose and they are approved for the same indications.
The pivotal clinical trials leading to dimethyl fumarate approval have been conducted with the original trademark Tecfidera®. No clinical trials with Catira® or Dimeful® have been found. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Argentina; Dimethyl Fumarate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting Language Published Spanish Country of organisation Argentina English summary There is no English language summary available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32017000298 Date abstract record published 13/06/2017 |
|
|
|